Efficacy
SARS-CoV-2-specific T-cell memory
ASYMPTOMATIC COVID-19, EVENTS, SARS-COV-2 INFECTION
Evaluation of the ELISPOT assay test shows that 38.8% of subjects were reactive to SARS-CoV-2 S protein (significant increase of spot count) at day 14. This number increases where 62.2% of subjects were reactive to SARS-CoV-2 S protein at day 14 or day 28 (SARS-CoV-2-specific T-cell memory response.
In a 1-year observation of the subjects of the phase I clinical trial, eight people were confirmed positive for SARS-CoV-2 infection, all of whom were mild clinical symptoms and did not require hospital treatment (The number of mild symptomatic COVID-19 events from 3rd to 12thmonths in phase I subjects. No severe symptomatic COVID-19 events were observed.The number of mild and severe symptomatic COVID-19 events from 3rd to 12th months in phase II subjects. No significant difference between dose group (p>0.05).